Real-World Data Underscore Lenire Outcomes in U.S. Tinnitus Patients

According to a recent LinkedIn post from Neuromod Devices Ltd, new real-world data on its Lenire device for tinnitus treatment have been highlighted from a paper by Dr. Craig Kasper of NYHD | Institute For Hearing & Balance. The analysis covers 140 U.S. tinnitus patients and reports that 81.8% experienced relief, with a mean reduction of 23.8 points on the Tinnitus Handicap Inventory scale.

The post notes that these findings, published in ASHA Journals, appear consistent with an earlier real-world analysis of U.S. patients treated with Lenire that was published in Nature Portfolio. For investors, the reinforcement of clinically relevant outcomes in independent publications may support Lenire’s credibility, potentially aiding physician adoption, reimbursement discussions, and Neuromod Devices’ competitive position in the tinnitus-treatment market.